Shoni Health Ventures

Voll Medical Technologies is a stealth-mode company, focusing on developing innovative medical technologies.

Fully automated diagnosis, interpretation & reporting of ultrasound examinations at the point of care.

Lin Health is a digital platform that focuses on providing comprehensive care for individuals suffering from chronic pain. It offers personalized, science-based programs developed by experts to address patients' unique needs. By leveraging telehealth services, Lin Health connects patients to a remote care system, facilitating access to non-opioid treatments and integrated behavioral health therapy. This approach aims to effectively diagnose and manage chronic pain, ultimately helping patients to improve their well-being and quality of life.

QuantHealth develops artificial intelligence-based software aimed at enhancing drug development processes. The company's platform conducts patient-centric simulations that integrate various data points from the clinical and drug development landscape. By predicting patient responses to both existing and new therapies, QuantHealth enables pharmaceutical and biotechnology companies to test different clinical trial designs. This capability helps optimize trial strategies, ultimately increasing the chances of successful outcomes. Through its innovative approach, QuantHealth supports the healthcare industry in identifying new clinical opportunities and refining development strategies.

FeelBetter is a healthcare optimization platform founded in 2018 and based in Tel Aviv, Israel. The company focuses on value-based models to identify at-risk patients and recommend appropriate interventions. Its platform enhances both financial and clinical outcomes by analyzing individual health journeys, allowing healthcare organizations to diagnose potential issues before they escalate. By delivering personalized data and actionable insights, FeelBetter aims to improve the quality of care and overall business results for healthcare providers.

Append Medical is focused on developing a next-generation transcatheter Left Atrial Appendage (LAA) closure system, aimed at preventing strokes by mitigating the risk of blood clot leakage to the brain. Currently in the pre-clinical in-vivo trial phase, the company's innovative approach involves tissue invagination and closure by suture, rather than traditional implants. This method is designed to simplify the treatment of atrial fibrillation while minimizing the presence of foreign materials at the closure site, thereby reducing the risk of device-related thromboembolism. The LAA closure market is anticipated to grow significantly, with estimates suggesting it could reach $25 billion in the coming years. Append Medical is also a participant in MEDX Xelerator, a medtech incubator supported by various industry leaders.

Stealth mode

Fully automated diagnosis, interpretation & reporting of ultrasound examinations at the point of care.